Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tandem Diabetes Care (TNDM) EBITDA (2016 - 2025)

Historic EBITDA for Tandem Diabetes Care (TNDM) over the last 13 years, with Q3 2025 value amounting to -$19.7 million.

  • Tandem Diabetes Care's EBITDA fell 890.34% to -$19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$202.1 million, marking a year-over-year decrease of 6740.51%. This contributed to the annual value of -$99.3 million for FY2024, which is 5472.67% up from last year.
  • Tandem Diabetes Care's EBITDA amounted to -$19.7 million in Q3 2025, which was down 890.34% from -$48.7 million recorded in Q2 2025.
  • In the past 5 years, Tandem Diabetes Care's EBITDA registered a high of $10.2 million during Q4 2021, and its lowest value of -$128.5 million during Q1 2025.
  • For the 5-year period, Tandem Diabetes Care's EBITDA averaged around -$31.4 million, with its median value being -$19.7 million (2025).
  • Its EBITDA has fluctuated over the past 5 years, first surged by 16240.15% in 2021, then tumbled by 96091.02% in 2022.
  • Quarter analysis of 5 years shows Tandem Diabetes Care's EBITDA stood at $10.2 million in 2021, then plummeted by 223.86% to -$12.6 million in 2022, then crashed by 109.64% to -$26.4 million in 2023, then skyrocketed by 80.85% to -$5.1 million in 2024, then plummeted by 290.0% to -$19.7 million in 2025.
  • Its EBITDA stands at -$19.7 million for Q3 2025, versus -$48.7 million for Q2 2025 and -$128.5 million for Q1 2025.